Tadalafil (Generic) vs Vardenafil (Levitra/Staxyn): Switching Between Them

What Are Tadalafil and Vardenafil, and How Do They Work?

Both drugs block phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. When PDE5 is inhibited, cGMP accumulates, smooth muscle relaxes, and blood flow into the corpora cavernosa increases in response to sexual stimulation. Neither drug causes an erection without arousal.

Shared Mechanism, Different Pharmacokinetics

The two molecules reach the same target but travel differently through the body. Tadalafil has a half-life of approximately 17.5 hours, which explains its 36-hour window of action. Vardenafil's half-life is roughly 4 to 5 hours, limiting its effective window to about 4 to 6 hours after dosing. FDA prescribing information for both agents confirms these pharmacokinetic differences.

Selectivity Differences That Affect Side-Effect Profiles

Vardenafil is approximately 10-fold more potent against PDE5 than sildenafil and shows somewhat less activity at PDE6 (the retinal isoform), which may translate to a lower rate of visual side effects. Tadalafil inhibits PDE11 in addition to PDE5; PDE11 is expressed in skeletal muscle and the testes, and some patients report mild myalgia with daily tadalafil use. These selectivity differences help explain why a patient who tolerates one drug poorly may respond differently to the other. The FDA label for tadalafil (Cialis) and the FDA label for vardenafil (Levitra) list distinct adverse-event profiles for this reason.

Tadalafil Generic: Doses, Indications, and Who Benefits Most

Tadalafil is available as 2.5 mg, 5 mg, 10 mg, and 20 mg tablets. The 10 mg on-demand starting dose is appropriate for most men; the 20 mg dose is used when 10 mg fails. Daily 2.5 to 5 mg dosing eliminates the need to time intercourse and is the only oral ED medication also FDA-approved to treat lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH).

The Brock et al. 2002 Trial: Establishing Daily Dosing

Brock et al. (J Urol 2002) was among the first rigorous studies to demonstrate that tadalafil produced sustained improvements in erectile function with both on-demand and once-daily protocols, showing a longer duration of action than sildenafil and specific benefit for men whose LUTS complicated their ED management. The study established the pharmacodynamic basis for daily dosing. The clinical implication is direct: a man with both ED and BPH who prefers a single once-daily tablet gains two approved indications from tadalafil 5 mg that vardenafil cannot offer.

Food and Alcohol Interactions

Tadalafil absorption is not meaningfully affected by a high-fat meal. A man who prefers to eat before intimacy without worrying about pharmacokinetic delays benefits from this property. Alcohol at moderate levels does not interact significantly, though heavy use increases hypotensive risk with any PDE5 inhibitor.

Who Typically Does Best on Tadalafil

• Men who want scheduling flexibility over an entire weekend
• Men with comorbid LUTS/BPH on daily 5 mg dosing
• Men who find on-demand timing stressful and prefer daily low-dose therapy
• Men whose partners have unpredictable availability

Vardenafil (Levitra/Staxyn): Doses, Formulations, and Who Benefits Most

Vardenafil is available as standard film-coated tablets (Levitra: 5 mg, 10 mg, 20 mg) and as an orodispersible tablet (Staxyn: 10 mg). The orodispersible form dissolves on the tongue without water, which some men prefer for convenience or discretion. The recommended starting dose is 10 mg taken 25 to 60 minutes before sexual activity.

The Porst et al. 2003 Trial: Diabetic ED Population

Porst et al. (Int J Impot Res 2003) evaluated vardenafil specifically in men with diabetes-related ED, a population in whom vascular and neuropathic damage makes treatment more challenging. At standard doses, vardenafil produced statistically significant improvements in erectile function scores compared with placebo, demonstrating efficacy even in this harder-to-treat group. Diabetic ED is associated with lower baseline response rates to PDE5 inhibitors generally, so evidence of efficacy in this population is clinically meaningful when counseling patients with type 2 diabetes.

Food Interaction: The High-Fat Meal Problem

A high-fat meal reduces vardenafil's peak plasma concentration (Cmax) by approximately 18 to 50% and delays time to peak. Men who anticipate eating a fatty meal before sex should take vardenafil at least 2 hours before the meal, or consider switching to tadalafil. The orodispersible Staxyn formulation is not interchangeable with film-coated Levitra tablets on a mg-for-mg basis and should not be substituted without a new prescription.

QTc Prolongation Signal

Vardenafil carries a labeling note about QTc interval prolongation. The effect is modest at therapeutic doses, but men taking Class IA or Class III antiarrhythmics (quinidine, amiodarone, sotalol) should not use vardenafil. Tadalafil has no comparable QTc signal at approved doses, which is a relevant difference for patients with cardiac arrhythmia histories.

Who Typically Does Best on Vardenafil

• Men who prefer a short, defined window of action
• Men with diabetes who have not responded adequately to other PDE5 inhibitors
• Men who want a discreet orodispersible option (Staxyn 10 mg)
• Men without arrhythmia history who tolerate the 4 to 6-hour window

Direct Comparison: Tadalafil vs Vardenafil Across Key Clinical Dimensions

No large-scale, randomized head-to-head trial has directly compared tadalafil and vardenafil in the same study with pre-specified primary endpoints. That evidence gap matters. The comparisons below draw from independent trial data and published pharmacokinetic analyses, not from a single H2H study.

Onset of Action

Tadalafil on-demand typically reaches effective plasma levels within 30 to 45 minutes, with the prescribing label suggesting dosing at least 30 minutes before activity. Vardenafil works slightly faster in some studies, with meaningful plasma levels at 25 to 30 minutes. Neither drug's onset difference is large enough to be clinically decisive for most patients.

Duration of Action

This is the clearest differentiator. Tadalafil's 36-hour window means a single Friday-evening dose may remain active through Sunday. Vardenafil's 4 to 6-hour window does not. For men who value spontaneity over an extended period, tadalafil is the more practical choice. For men who want a clean pharmacological window with less carryover, vardenafil is preferable.

Efficacy in General ED Populations

Both drugs improve International Index of Erectile Function (IIEF) scores significantly versus placebo. Across registration trials, tadalafil 20 mg on-demand improved successful intercourse attempts in approximately 75% of patients versus roughly 32% for placebo. Vardenafil 20 mg produced successful penetration rates of 70 to 80% in key trials. A 2006 meta-analysis in the European Urology journal examined response rates across PDE5 inhibitor trials and found no statistically significant efficacy difference between agents at maximal doses, though individual patient response varies.

Side-Effect Comparison

| Side Effect | Tadalafil | Vardenafil | |---|---|---| | Headache | 11 to 15% | 10 to 16% | | Flushing | 4 to 9% | 10 to 11% | | Dyspepsia | 4 to 12% | 3 to 4% | | Back pain / myalgia | 3 to 6% (PDE11) | <2% | | Rhinitis | 3 to 4% | 9 to 10% | | Visual disturbance | <2% | <2% | | QTc prolongation | Not significant | Mild, dose-dependent |

Tadalafil's higher rate of back pain and myalgia traces to its PDE11 activity. Vardenafil's higher rhinitis rate is consistent across trials. Neither difference is typically treatment-limiting, but they inform switching decisions.

Contraindication Overlap

Both drugs share the same absolute contraindication: concurrent use of organic nitrates in any form (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite). The hemodynamic interaction can cause severe, potentially fatal hypotension. FDA prescribing information for both agents classifies nitrate co-administration as a contraindication. The nitrate washout period before starting either PDE5 inhibitor must be discussed with the prescribing physician; guidelines vary by nitrate formulation and duration of use.

Switching Between Tadalafil and Vardenafil: A Clinical Protocol

Switching is medically straightforward when done correctly. There is no required washout period between the two drugs under typical clinical conditions, because neither agent has documented pharmacodynamic interactions with the other and their combined use is not indicated (two PDE5 inhibitors should never be taken simultaneously).

The HealthRX Switching Framework

The following decision steps summarize how the HealthRX medical team approaches a switch request from tadalafil to vardenafil or vice versa:

Step 1. Clarify why the switch is requested. The reason changes the approach. Inadequate efficacy suggests a dose issue first. Specific side effects (back pain on tadalafil, rhinitis on vardenafil) suggest a class switch. Lifestyle mismatch (wanting shorter duration) points directly to vardenafil.

Step 2. Confirm no contraindications to the target drug. Check for nitrate use (absolute contraindication for both). For vardenafil, confirm no Class IA/III antiarrhythmics and no significant QTc prolongation on recent ECG. For tadalafil, confirm no alpha-blocker co-administration without appropriate dose separation.

Step 3. Stop the first drug and start the second at standard starting dose. Do not double-dose or overlap. Stop tadalafil (on-demand or daily). Start vardenafil 10 mg on-demand at the next attempt. Or stop vardenafil and start tadalafil 10 mg on-demand (or 2.5 mg daily if daily dosing is preferred).

Step 4. Allow 4 to 6 attempts before judging efficacy. A single failed attempt does not indicate drug failure. Anxiety, alcohol, fatigue, and timing errors all confound the first few uses. The AUA Guidelines on Erectile Dysfunction recommend adequate dose titration and sufficient trial duration before concluding failure.

Step 5. Titrate if needed. Vardenafil: step up from 10 mg to 20 mg if response is partial. Tadalafil on-demand: step up from 10 mg to 20 mg. Tadalafil daily: step from 2.5 mg to 5 mg after 2 to 4 weeks.

Patients Most Likely to Benefit from Switching

Switching is most productive in these clinical scenarios:

• Tadalafil to vardenafil: persistent back pain or myalgia on tadalafil, desire for shorter action window, partner preference for a defined timeframe
• Vardenafil to tadalafil: dietary restrictions that conflict with high-fat meal interaction, comorbid BPH/LUTS needing dual treatment, desire for weekend-long coverage

When a Switch Is Unlikely to Help

If a patient has failed both on-demand tadalafil 20 mg and vardenafil 20 mg, the issue is rarely a drug-class preference problem. Severe vascular disease, uncontrolled diabetes (HbA1c above 9%), hypogonadism (total testosterone below 300 ng/dL), or psychogenic ED refractory to both oral agents warrants a broader evaluation. Intraurethral alprostadil, intracavernosal injection therapy, or vacuum erection devices may be appropriate next steps. A 2010 review in the Journal of Sexual Medicine outlined the sequential algorithm for ED treatment escalation.

Special Populations: Which Drug Fits Which Patient?

Diabetes and Metabolic Syndrome

Porst et al. (Int J Impot Res 2003) showed vardenafil's efficacy in diabetic men. Tadalafil has similarly demonstrated benefit in metabolic syndrome-related ED in multiple trials. Neither drug clearly outperforms the other in diabetic populations when matched by dose, but vardenafil's trial database in this group is larger.

Cardiovascular Disease

Both drugs are vasodilatory and share the same blood-pressure-lowering profile at therapeutic doses. The Princeton Consensus guidelines (third panel, 2012) stratify cardiovascular risk for PDE5 inhibitor use. Men in the low-risk category can use either drug. Vardenafil's QTc signal makes it the drug to avoid in men with prolonged QT syndrome or on QT-prolonging medications.

Older Men and Renal/Hepatic Impairment

Tadalafil's area under the curve (AUC) increases approximately 88% in men with severe renal impairment (creatinine clearance <30 mL/min), requiring dose reduction. Vardenafil's AUC increases approximately 52% in moderate hepatic impairment (Child-Pugh B), requiring a maximum starting dose of 5 mg. Both drugs warrant caution in these populations, but the specific dose adjustments differ. Physicians should consult current FDA labeling for exact dosing guidance.

Men on Alpha-Blockers

Both drugs lower blood pressure when combined with alpha-blockers, but the magnitude and clinical significance differ somewhat by drug and timing. Tadalafil 5 mg daily has the most data in men simultaneously taking tamsulosin 0.4 mg for BPH. Vardenafil should not be co-administered with tamsulosin 0.4 mg in some formulations due to risk of symptomatic hypotension. The FDA label for vardenafil specifically restricts concurrent use with tamsulosin in the Staxyn formulation.

Cost, Availability, and Generic Access

Tadalafil lost patent exclusivity in the United States in 2018. Generic tadalafil is now widely available at costs as low as $1 to 3 per tablet at major pharmacy chains with discount programs, compared with brand Cialis at $30 to 70 per tablet. Vardenafil generics became available in 2018 as well, with similar cost reduction, though Staxyn (the orodispersible formulation) has had more limited generic competition and may remain more expensive. GoodRx and similar platforms confirm significant price variability by pharmacy and region.

For men paying out of pocket, tadalafil generic typically offers the lowest per-dose cost at the 5 mg daily dosing level, particularly when ordered through telehealth platforms with volume pricing. This cost difference alone drives many switches from branded vardenafil (Levitra) to generic tadalafil in practice.

Patient-Reported Preferences: What Real Survey Data Show

A 2013 patient-preference study published in the Journal of Sexual Medicine surveyed 1,057 men who had used both tadalafil and sildenafil (not vardenafil) and found that 63% preferred tadalafil for its duration of action. Direct tadalafil-vs-vardenafil preference data from randomized crossover trials are sparse, but the available evidence suggests that men who have tried multiple PDE5 inhibitors most frequently cite duration of action and side-effect profile, not efficacy per se, as the deciding factors. A 2004 patient-preference analysis in Urology identified spontaneity and reduced planning anxiety as the primary drivers of long-acting agent preference.

The clinical takeaway is that efficacy is roughly comparable between agents at maximum doses. The decision ultimately rests on lifestyle fit, tolerability, and comorbidities.

Guideline Positions on PDE5 Inhibitor Selection

The American Urological Association (AUA) 2018 ED Guidelines state: "PDE5 inhibitors (sildenafil, tadalafil, vardenafil, and avanafil) are recommended as first-line therapy for erectile dysfunction in appropriately selected patients." The full guideline text is accessible through the AUA.

The European Association of Urology (EAU) 2023 Guidelines on Sexual and Reproductive Health similarly position all four PDE5 inhibitors as first-line agents with equivalent evidence grade (1a, recommendation grade A), noting that individual patient factors should drive agent selection rather than any assumed superiority of one drug. The EAU guidelines are hosted on their official platform.

Neither guideline specifies a preferred sequence for switching between agents. Both indicate that failure of one PDE5 inhibitor at maximum dose, confirmed over at least 4 to 6 attempts, should prompt evaluation for contributing factors before escalating to second-line therapy.

Practical Dosing Reference

Tadalafil Dosing Schedule

• On-demand: 10 mg starting dose, 30 minutes before activity; may increase to 20 mg or decrease to 5 mg based on response and tolerability
• Daily: 2.5 mg once daily, regardless of timing relative to sexual activity; may increase to 5 mg
• BPH/LUTS: 5 mg once daily
• Maximum frequency (on-demand): once per 24 hours
• Renal adjustment: avoid in severe impairment (CrCl <30 mL/min) on daily dosing; use with caution on demand

Vardenafil Dosing Schedule

• Film-coated tablet (Levitra): 10 mg starting dose, 25 to 60 minutes before activity; may increase to 20 mg or decrease to 5 mg
• Orodispersible (Staxyn): 10 mg only, placed on tongue 60 minutes before activity; do not exceed one tablet per day
• Maximum frequency: once per 24 hours
• Hepatic adjustment: start at 5 mg in Child-Pugh B; avoid in Child-Pugh C
• Not for use with tamsulosin (Staxyn formulation)